Mon panier

Biotinylated Cynomolgus IL-12 R beta 1 / CD212 Protein, His,Avitag™

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
ILB-C52E2-25ug
$360.00
ILB-C52E2-200ug
$1420.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    IL-12 R beta 1, IL12RB1, CD212, IL12R, IL12RB, IL-12RB1

  • Source

    Biotinylated Cynomolgus IL-12 R beta 1 , His,Avitag (ILB-C52E2) is expressed from human 293 cells (HEK293). It contains AA Cys 24 - Asp 545 (Accession # G7PWY9-1).

    Predicted N-terminus: Cys 24

    Request for sequence
  • Molecular Characterization

    IL-12 R beta 1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 61.0 kDa. The protein migrates as 80-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    IL-12 R beta 1 SDS-PAGE

    Biotinylated Cynomolgus IL-12 R beta 1 , His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Bioactivity-ELISA

     IL-12 R beta 1 ELISA

    Immobilized Biotinylated Cynomolgus IL-12 R beta 1 , His,Avitag (Cat. No. ILB-C52E2) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human IL-12B, Fc Tag (Cat. No. NK2-H5258) with a linear range of 0.1-8 ng/mL (QC tested).

    Protocol
  • Bioactivity-BLI

     IL-12 R beta 1 BLI

    Loaded Biotinylated Cynomolgus IL-12 R beta 1 , His,Avitag (Cat. No. ILB-C52E2) on SA Biosensor, can bind ActiveMax® Human IL-12 ,Tag Free (Cat. No. IL2-H5210) with an affinity constant of 1.9 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

The human IL-12 R subunit is a member of the cytokine receptor superfamily and the functional high-affinity IL-12R is composed of at least two beta-type cytokine receptor subunits, each independently exhibiting a low affinity for IL-12. IL-12 R beta 1 (Interleukin-12 receptor subunit beta-1) is also known as IL-12RB1, CD212. Functions as an interleukin receptor which binds interleukin-12 with low affinity and is involved in IL12 transduction. Associated with IL12RB2 it forms a functional, high affinity receptor for IL12. Associates also with IL23R to form the interleukin-23 receptor which functions in IL23 signal transduction probably through activation of the Jak-Stat signaling cascade.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Interleukin-12 receptor

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    9 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte